Ann Dermatol.  2019 Aug;31(4):469-472. 10.5021/ad.2019.31.4.469.

Comparative Study of Clinical Characteristics according to Therapeutic Efficacy and Drug Survival of Cyclosporine or Methotrexate in Psoriasis Vulgaris

• Lee HS
• Kwon SH
• Lee ES

• KMID: 2451491
• DOI: http://doi.org/10.5021/ad.2019.31.4.469

Abstract

No abstract available.

MeSH Terms

Cyclosporine*
Methotrexate*
Psoriasis*
Cyclosporine
Methotrexate

Figure

• 

  Fig. 1 (A) Cyclosporine (CsA) responders had the shortest disease duration among the methotrexate (MTX) responders, CsA non-responders, and MTX non-responders (45.1 vs. 80.8, 65.6, and 115.1 months, respectively). The disease duration of the CsA responders was significantly shorter than that of the MTX responders and non-responders (marked with asterisk). (B) The CsA responders showed the lowest initial serum erythrocyte sedimentation rate (ESR) level (10.1 vs. 11.3, 13.2, and 17.7 mm/h, respectively). The difference was statistically significant between the CsA responders and MTX non-responders (marked with asterisk).

Reference

1. Strober BE. Methotrexate and cyclosporine in psoriasis revisited. Semin Cutan Med Surg. 2014; 33:2 Suppl 2. S27–S30.

2. Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 2011; 36:845–850.

3. Zweegers J, Roosenboom B, van de Kerkhof PC, van den Reek JM, Otero ME, Atalay S, et al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol. 2017; 176:786–793.

4. Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016; 74:851–861.e4.

5. Menting SP, Sitaram AS, Bonnerjee-van der Stok HM, de Rie MA, Hooft L, Spuls PI. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014; 171:875–883.

6. van Lümig PP, van de Kerkhof PC, Boezeman JB, Driessen RJ, de Jong EM. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol. 2013; 27:593–600.

7. Shear NH, Hartmann M, Toledo-Bahena M, Katsambas A, Connors L, Chang Q, et al. REALITY investigators. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol. 2014; 171:631–641.